Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.46), $0.05 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $16.95 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Industrial Realty (FR) Tops Q1 EPS by 21c
- William Penn Bancorporation (WMPN) Tops Q3 EPS by 1c
- Taiwan Semi (TSM) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!